Arkolith/Insider Trading/PRLD/Form 4

Combs Andrew

Chief Chemistry OfficerPrelude Therapeutics Inc (PRLD) · full profile →Form 4 · filed Dec 26, 2024
Net Buying
Open-Market Buys
$86K
Open-Market Sells
$0
Net Open-Market Flow
$86K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 23, 2024Buy(P)60K$1.37$82K378K
Dec 20, 2024Buy(P)3K$1.15$4K318K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001562180-24-008565) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML